Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment

Status: Recruiting
Location: See all (152) locations...
Intervention Type: Combination product, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability. Study details include: * Participants can transition in ROSY-S once they complete their participation in the parent study and should have received at least one dose of anifrolumab in the parent study. Participants with a treatment gap from parent studies and/or who are on compassionate use are eligible to rollover to ROSY-S study. * The earliest that the Enrolment Visit may occur is at the time of the last visit of the parent study (ie, completion of the parent study's final safety follow-up visit). All required assessments from the safety follow-up visit of the parent study must be completed before the Enrolment Visit of ROSY-S study. * The participants will continue to receive anifrolumab the same way they received it in the parent trial * A participant is considered to have completed the study when they meet one of the discontinuation criteria. * Safety will be monitored throughout the study. Both serious and nonserious AEs will be collected up to 12 weeks after the last dose of anifrolumab and will be reported as part of the primary safety endpoint.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 80
Healthy Volunteers: f
View:

• Participants are eligible to be included in the study only if all of the following criteria apply:

• 1 Participants must have completed the entirety of the parent study and should have received at least one dose of anifrolumab in the parent study.

• In the opinion of the Investigator, the potential benefit to the participant of continuing anifrolumab at the end of the parent study outweighs the risk.

• Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Participants should continue following the contraception requirements as per Appendix B from study enrolment up to 16 weeks after the last dose of study treatment.

• Capable of giving signed informed consent described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

• Capable of adhering to the treatment plan related to this ROSY-S study.

Locations
United States
Arizona
Research Site
NOT_YET_RECRUITING
Phoenix
California
Research Site
RECRUITING
Los Angeles
Research Site
NOT_YET_RECRUITING
San Francisco
Florida
Research Site
RECRUITING
Boca Raton
Research Site
RECRUITING
Fort Lauderdale
Illinois
Research Site
NOT_YET_RECRUITING
Chicago
Indiana
Research Site
NOT_YET_RECRUITING
Indianapolis
Michigan
Research Site
NOT_YET_RECRUITING
Ann Arbor
Minnesota
Research Site
NOT_YET_RECRUITING
Rochester
North Carolina
Research Site
RECRUITING
Charlotte
Nebraska
Research Site
NOT_YET_RECRUITING
Omaha
New York
Research Site
NOT_YET_RECRUITING
New York
Ohio
Research Site
NOT_YET_RECRUITING
Cleveland
Research Site
NOT_YET_RECRUITING
Columbus
Oregon
Research Site
NOT_YET_RECRUITING
Portland
South Carolina
Research Site
NOT_YET_RECRUITING
Charleston
Texas
Research Site
NOT_YET_RECRUITING
Dallas
Virginia
Research Site
NOT_YET_RECRUITING
Roanoke
Other Locations
Argentina
Research Site
NOT_YET_RECRUITING
Quilmes
Research Site
NOT_YET_RECRUITING
San Miguel
Australia
Research Site
NOT_YET_RECRUITING
Melbourne
Research Site
NOT_YET_RECRUITING
Mitcham
Austria
Research Site
NOT_YET_RECRUITING
Graz
Research Site
NOT_YET_RECRUITING
Graz
Research Site
NOT_YET_RECRUITING
Linz
Research Site
NOT_YET_RECRUITING
Vienna
Belgium
Research Site
NOT_YET_RECRUITING
Ghent
Research Site
NOT_YET_RECRUITING
Leuven
Brazil
Research Site
NOT_YET_RECRUITING
Belo Horizonte
Research Site
NOT_YET_RECRUITING
Rio De Janeiro
Research Site
NOT_YET_RECRUITING
Salvador
Research Site
NOT_YET_RECRUITING
São Paulo
Bulgaria
Research Site
NOT_YET_RECRUITING
Plovdiv
Research Site
NOT_YET_RECRUITING
Sofia
Research Site
NOT_YET_RECRUITING
Sofia
Canada
Research Site
NOT_YET_RECRUITING
Québec
Chile
Research Site
NOT_YET_RECRUITING
Santiago
China
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Chongqing
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
NOT_YET_RECRUITING
Jinan
Research Site
NOT_YET_RECRUITING
Lanzhou
Research Site
NOT_YET_RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shenzhen
Research Site
NOT_YET_RECRUITING
Shenzhen
Colombia
Research Site
NOT_YET_RECRUITING
Bogotá
France
Research Site
NOT_YET_RECRUITING
Bordeaux
Research Site
NOT_YET_RECRUITING
Nantes
Research Site
NOT_YET_RECRUITING
Paris
Research Site
NOT_YET_RECRUITING
Paris
Research Site
NOT_YET_RECRUITING
Paris
Research Site
NOT_YET_RECRUITING
Poitiers
Research Site
NOT_YET_RECRUITING
Rennes
Research Site
NOT_YET_RECRUITING
Strasbourg
Research Site
NOT_YET_RECRUITING
Toulouse
Research Site
NOT_YET_RECRUITING
Toulouse
Germany
Research Site
NOT_YET_RECRUITING
Berlin
Research Site
NOT_YET_RECRUITING
Dresden
Research Site
NOT_YET_RECRUITING
Essen
Research Site
NOT_YET_RECRUITING
Freiburg Im Breisgau
Research Site
NOT_YET_RECRUITING
Freiburg Im Breisgau
Research Site
NOT_YET_RECRUITING
Hanover
Research Site
NOT_YET_RECRUITING
Kiel
Research Site
NOT_YET_RECRUITING
Mainz
Research Site
NOT_YET_RECRUITING
Marburg
Research Site
NOT_YET_RECRUITING
Münster
Research Site
NOT_YET_RECRUITING
Regensburg
Research Site
NOT_YET_RECRUITING
Tübingen
Research Site
NOT_YET_RECRUITING
Wuppertal
Greece
Research Site
NOT_YET_RECRUITING
Chaïdári
India
Research Site
NOT_YET_RECRUITING
Hyderabad
Research Site
NOT_YET_RECRUITING
Kolkata
Research Site
NOT_YET_RECRUITING
New Delhi
Research Site
NOT_YET_RECRUITING
Pune
Israel
Research Site
NOT_YET_RECRUITING
Haifa
Research Site
NOT_YET_RECRUITING
Kfar Saba
Italy
Research Site
NOT_YET_RECRUITING
Brescia
Research Site
NOT_YET_RECRUITING
Catania
Research Site
NOT_YET_RECRUITING
Cona
Research Site
NOT_YET_RECRUITING
Florence
Research Site
NOT_YET_RECRUITING
Milan
Research Site
NOT_YET_RECRUITING
Milan
Research Site
NOT_YET_RECRUITING
Pavia
Research Site
NOT_YET_RECRUITING
Roma
Research Site
NOT_YET_RECRUITING
Roma
Japan
Research Site
NOT_YET_RECRUITING
Fukuoka
Research Site
NOT_YET_RECRUITING
Kanazawa
Research Site
NOT_YET_RECRUITING
Maebashi
Research Site
NOT_YET_RECRUITING
Nagoya
Research Site
NOT_YET_RECRUITING
Sapporo
Research Site
NOT_YET_RECRUITING
Yokohama
Mexico
Research Site
NOT_YET_RECRUITING
Guadalajara
Research Site
NOT_YET_RECRUITING
Guadalajara
Research Site
NOT_YET_RECRUITING
San Luis Potosí City
Research Site
NOT_YET_RECRUITING
Veracruz
Netherlands
Research Site
NOT_YET_RECRUITING
Rotterdam
Philippines
Research Site
NOT_YET_RECRUITING
Iloilo City
Research Site
NOT_YET_RECRUITING
Lipa City
Research Site
NOT_YET_RECRUITING
Manila
Poland
Research Site
NOT_YET_RECRUITING
Bydgoszcz
Research Site
NOT_YET_RECRUITING
Katowice
Research Site
NOT_YET_RECRUITING
Kielce
Research Site
NOT_YET_RECRUITING
Krakow
Research Site
NOT_YET_RECRUITING
Krakow
Research Site
NOT_YET_RECRUITING
Lodz
Research Site
NOT_YET_RECRUITING
Ossy
Research Site
NOT_YET_RECRUITING
Warsaw
Portugal
Research Site
NOT_YET_RECRUITING
Braga
Research Site
NOT_YET_RECRUITING
Lisbon
Research Site
NOT_YET_RECRUITING
Porto
Republic of Korea
Research Site
NOT_YET_RECRUITING
Seoul
Research Site
NOT_YET_RECRUITING
Seoul
Research Site
NOT_YET_RECRUITING
Seoul
Research Site
NOT_YET_RECRUITING
Seoul
Romania
Research Site
NOT_YET_RECRUITING
Bucharest
Research Site
NOT_YET_RECRUITING
Cluj-napoca
Research Site
NOT_YET_RECRUITING
Iași
Serbia
Research Site
NOT_YET_RECRUITING
Belgrade
Research Site
NOT_YET_RECRUITING
Kragujevac
Slovakia
Research Site
NOT_YET_RECRUITING
Košice
Research Site
NOT_YET_RECRUITING
Piešťany
South Africa
Research Site
NOT_YET_RECRUITING
Johannesburg
Spain
Research Site
NOT_YET_RECRUITING
A Coruña
Research Site
NOT_YET_RECRUITING
Barcelona
Research Site
NOT_YET_RECRUITING
Barcelona
Research Site
NOT_YET_RECRUITING
Castellon
Research Site
NOT_YET_RECRUITING
Granada
Research Site
NOT_YET_RECRUITING
Las Palmas De Gran Canaria
Research Site
NOT_YET_RECRUITING
Madrid
Research Site
NOT_YET_RECRUITING
Madrid
Research Site
NOT_YET_RECRUITING
Valencia
Research Site
NOT_YET_RECRUITING
Valencia
Research Site
NOT_YET_RECRUITING
Valladolid
Research Site
NOT_YET_RECRUITING
Vigo
Taiwan
Research Site
NOT_YET_RECRUITING
Kaohsiung City
Research Site
NOT_YET_RECRUITING
Kaohsiung City
Research Site
NOT_YET_RECRUITING
Taichung
Research Site
NOT_YET_RECRUITING
Taipei
Thailand
Research Site
NOT_YET_RECRUITING
Bangkok
Research Site
NOT_YET_RECRUITING
Bangkok
Research Site
NOT_YET_RECRUITING
Hat Yai
Research Site
NOT_YET_RECRUITING
Khon Kaen
Research Site
NOT_YET_RECRUITING
Klong Luang
Turkey
Research Site
NOT_YET_RECRUITING
Fatih-istanbul
Research Site
NOT_YET_RECRUITING
Ümraniye
United Kingdom
Research Site
NOT_YET_RECRUITING
Cambridge
Research Site
NOT_YET_RECRUITING
Leeds
Research Site
NOT_YET_RECRUITING
London
Research Site
NOT_YET_RECRUITING
London
Research Site
NOT_YET_RECRUITING
Newcastle Upon Tyne
Research Site
NOT_YET_RECRUITING
Sheffield
Viet Nam
Research Site
NOT_YET_RECRUITING
Hà Nội
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
+1877-240-9479
Time Frame
Start Date: 2026-08-31
Estimated Completion Date: 2032-12-30
Participants
Target number of participants: 1072
Treatments
Experimental: Anifrolumab
This is a single arm open-label study with the primary objective of providing continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment and assessing long-term safety and tolerability of anifrolumab until participant meets one of the study discontinuation criteria.
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov